Cargando…
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192842/ https://www.ncbi.nlm.nih.gov/pubmed/31827243 http://dx.doi.org/10.1038/s41375-019-0658-7 |
| _version_ | 1783528077504020480 |
|---|---|
| author | Rule, Simon A. Cartron, Guillaume Fegan, Christopher Morschhauser, Franck Han, Lingling Mitra, Siddhartha Salles, Gilles Dyer, Martin J. S. |
| author_facet | Rule, Simon A. Cartron, Guillaume Fegan, Christopher Morschhauser, Franck Han, Lingling Mitra, Siddhartha Salles, Gilles Dyer, Martin J. S. |
| author_sort | Rule, Simon A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7192842 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71928422020-05-05 Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) Rule, Simon A. Cartron, Guillaume Fegan, Christopher Morschhauser, Franck Han, Lingling Mitra, Siddhartha Salles, Gilles Dyer, Martin J. S. Leukemia Letter Nature Publishing Group UK 2019-12-11 2020 /pmc/articles/PMC7192842/ /pubmed/31827243 http://dx.doi.org/10.1038/s41375-019-0658-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter Rule, Simon A. Cartron, Guillaume Fegan, Christopher Morschhauser, Franck Han, Lingling Mitra, Siddhartha Salles, Gilles Dyer, Martin J. S. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title | Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title_full | Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title_fullStr | Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title_full_unstemmed | Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title_short | Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) |
| title_sort | long-term follow-up of patients with mantle cell lymphoma (mcl) treated with the selective bruton’s tyrosine kinase inhibitor tirabrutinib (gs/ono-4059) |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192842/ https://www.ncbi.nlm.nih.gov/pubmed/31827243 http://dx.doi.org/10.1038/s41375-019-0658-7 |
| work_keys_str_mv | AT rulesimona longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT cartronguillaume longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT feganchristopher longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT morschhauserfranck longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT hanlingling longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT mitrasiddhartha longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT sallesgilles longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 AT dyermartinjs longtermfollowupofpatientswithmantlecelllymphomamcltreatedwiththeselectivebrutonstyrosinekinaseinhibitortirabrutinibgsono4059 |